Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Last updated: September 8, 2025
Sponsor: Travera Inc
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pancreatic Cancer

Cervical Cancer

Esophageal Disorders

Treatment

N/A

Clinical Study ID

NCT05461430
TRV-003
  • Ages > 18
  • All Genders

Study Summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patient is ≥18 years of age

  2. Written Informed Consent provided by patient

  3. Diagnosis of any kind of carcinoma

  4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissueresection OR tumor tissue needle biopsy is clinically indicated as part of SOC

  5. Proceeding onto therapy for treatment

  6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion

Exclusion Criteria:

  1. Lack of informed consent

  2. Unable to obtain sufficient sample

Study Design

Total Participants: 200
Study Start date:
July 15, 2022
Estimated Completion Date:
July 31, 2028

Connect with a study center

  • xCures

    Oakland, California 94612
    United States

    Site Not Available

  • xCures

    Oakland 5378538, California 5332921 94612
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.